Health News

Aspirin underutilized for preeclampsia prevention

(HealthDay)—Aspirin use is underused for preeclampsia prophylaxis in women with prepregnancy diabetes, obesity, or chronic hypertension or a combination of these factors, according to a research letter published in the Jan. 25 issue of the Journal of the American Medical Association.

Joel G. Ray, M.D., from St. Michael’s Hospital in Toronto, and colleagues used data from the Better Outcomes Registry and Network to identify with a hospital livebirth or stillbirth at ≥23 weeks of gestation (371,237 births; April 1, 2018, through Dec. 31, 2020) to estimate aspirin use for preeclampsia prevention in with prepregnancy diabetes, obesity, , and combinations of these factors.

The researchers found that aspirin was used by 3.2 percent of women without any of the three versus 17.2 percent of women with diabetes, 6.9 percent of women with obesity, and 27.6 percent of women with hypertension. For women with diabetes and obesity, the rate of aspirin use was 22.2 percent versus 36.6 percent in women with diabetes and hypertension, 32.3 percent in women with obesity and hypertension, and 38.8 percent in women with all three factors.

“For the 2021 U.S. Preventive Services Task Force recommendations to be more influential, more data are needed to characterize barriers for aspirin adoption among suitable women at the patient and practitioner level, and additional knowledge translation initiatives developed,” the authors write.

Glucose levels tied to maternal mortality even without diabetes

More information:
Abstract/Full Text (subscription or payment may be required)

Copyright © 2021 HealthDay. All rights reserved.

Aspirin underutilized for preeclampsia prevention (2022, January 31)
retrieved 31 January 2022

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Source link